September 21, 2017 6:16 PM ET


Company Overview of ILEX Oncology Inc.

Company Overview

As of December 20, 2004, ILEX Oncology Inc. was acquired by Genzyme Corp. ILEX Oncology, Inc. engages in the development and commercialization of therapeutic treatments, primarily in oncology. Its lead product is marketed as CAMPATH in the United States and as MABCAMPATH in Europe and other countries for the treatment of patients with B-cell chronic lymphocytic leukemia, a type of blood cancer characterized by progressive accumulation of B-lymphocytes. The company’s pipeline comprises product candidates at various stages of preclinical and clinical development, including Clofarabine, ILX-651, APOMINE, and NM-3. Clofarabine is a purine nucleoside antimetabolite for pediatric and adult leukemi...

4545 Horizon Hill Boulevard

San Antonio, TX 78229

United States

Founded in 1992

216 Employees





Key Executives for ILEX Oncology Inc.

ILEX Oncology Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ILEX Oncology Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at